Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XS411 iPSC-derived dopaminergic neural progenitor cells in early-onset Parkinson's disease
NCT07166757Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of XS-411 in Parkinson's disease (PD). Started Sep 2025; status: recruiting.
02
Drugs
XS-411
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07166757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166757.